New report projects big growth in CNS biomarker market; Empire Genomics grabs biomarker for prostate cancer;

> A new report from BCC Research concludes that the CNS biomarker market, worth $2 billion in 2012, will grow to $5.1 billion in 2017. Factors driving that growth include an aging population alongside the growth of new public/private partnerships. Release

> Empire Genomics has grabbed a license for a biomarker that could be used to develop a new diagnostic test for neuroendocrine prostate cancer. Empire did the deal with Cornell. Report

> Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer--one of a handful identified to date in Caucasians. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.